Several other equities analysts also recently weighed in on MSTX. Zacks Investment Research downgraded shares of Mast Therapeutics from a buy rating to a hold rating in a report on Tuesday, July 12th. Laidlaw downgraded shares of Mast Therapeutics from a buy rating to a neutral rating in a report on Wednesday, September 21st. Maxim Group reiterated a buy rating and set a $5.00 price target on shares of Mast Therapeutics in a report on Tuesday, July 12th. Canaccord Genuity reiterated a buy rating and set a $3.00 price target on shares of Mast Therapeutics in a report on Thursday, July 28th. Finally, Roth Capital reiterated a buy rating and set a $2.00 price target on shares of Mast Therapeutics in a report on Friday, July 15th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $2.07.
Shares of Mast Therapeutics (NASDAQ:MSTX) traded up 7.6250% during midday trading on Friday, reaching $0.0861. 5,968,621 shares of the company traded hands. The stock’s market capitalization is $18.24 million. The company’s 50 day moving average is $0.32 and its 200-day moving average is $0.36. Mast Therapeutics has a 12 month low of $0.08 and a 12 month high of $0.71.
Mast Therapeutics (NASDAQ:MSTX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities research analysts forecast that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. increased its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.